University of Patras
Σχεδιασμός, σύνθεση και αποτίμηση της βιολογικής δράσης νέων ετεροκυκλικών ενώσεων που επάγουν τη δράση της διαλυτής γουανυλικής κυκλάσης
Abstract
dc:descriptionSoluble guanylyl cyclase (sGC) is a heterodimeric enzyme that catalyzes the conversion of GTP to cGMP upon binding of endogenously produced NO to a prosthetic heme moiety, located in the regulatory β1 Heme-NO OXygen (H-NOX) domain. Diminished NO bioavailability or impaired sGC sensitivity to the endogenous ligand due to loss of the heme moiety in oxidative stress conditions, could lead to dysregulation of NO/sCG/cGMP signaling axis. The consequences of this have best been described regarding the cardiovascular system, where it contributes to dysfunction of vascular smooth muscle and endothelial cells, ultimately leading to hypertension, inflammation, heart hypertrophy and heart failure. In addition, this axis maintains homeostasis in other systems and its dysregulation can lead to e.g. fibrosis in multiple organs or altered metabolic (adipose) function. During the last decades, two classes of novel pharmacological agents have been developed for the treatment of these diseases, sGC stimulators and activators, aiming to restore or augment enzymatic activity of the NO-insensitive forms of sGC in a heme-dependent or heme-independent manner, respectively. The present study focused on the discovery of new chemical entities which can act as sGC agonists. In particular, several rational drug design approaches, such as docking studies and analysis of previously reported structure-activity relationship studies of known sGC agonists, were applied for the targeted design of novel sGC agonists. Based on the obtained findings, new heterocycles, such as 3,4-dihydroquinoxalinone and pyrazolo[3,4-c]pyridone derivatives, were designed as potential sGC activators and stimulators, respectively. Subsequently, the synthesis of the designed molecules was thoroughly investigated. The synthesis of the new compounds was accomplished through an efficient synthetic plan which involved the construction of the heterocyclic skeletons using appropriate precursors and the introduction of desirable substituents at specific positions of these heterocyclic cores. Finally, a preliminary biological evaluation of selected, newly synthesized 3,4-dihydroquinoxalinone and pyrazolo[3,4-c]pyridone derivatives was conducted in in vitro biological assays concerning their ability to induce the enzymatic activity of sGC. Although the tested 3,4-dihydroquinoxalinone derivatives did not provoke any significant increase of cGMP levels during cell-based assessment, further studies of these compounds on purified recombinant sGC revealed activation of the enzyme, even after loss of heme. Furthermore, selected pyrazolo[3,4-c]pyridone derivatives exhibited sGC stimulating activity by potentiating the effect of NO on A7r5 smooth muscle and HUVEC endothelial cells and, consequently, promoting anti-proliferative and anti-inflammatory activities on these cell models and contributing to an overall vascular protective function.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kintos, Dionysios - Panagiotis
- Κίντος, Διονύσιος-Παναγιώτης
Subjects
dc:subject × 16- Διαλυτή γουανυλική κυκλάση
- Ενεργοποιητές sGC
- Διεγέρτες sGC
- 3,4-διϋδροκινοξαλινόνη
- Πυραζολο[3,4-c]πυριδόνη
- Soluble guanylyl cyclase
- sGC activators
- sGC stimulators
- 3,4-dihydroquinoxalinone
- Pyrazolo[3,4-c]pyridone
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακευτική χημεία
- Basic Medicine
- Medical and Health Sciences
- Medicinal chemistry
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55748